Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 15/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.35 |
| ▸ | MERTK | Q12866 | 1/20 | 0.35 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18638062 | 0.97 | TLR8 (0.46) | TLR8TLR7CYP1A2ADORA2AADORA1 | |
| SCHEMBL18638438 | 0.94 | TLR8 (0.55) | TLR8TLR7 | |
| SCHEMBL18109480 | 0.84 | TLR8 (0.62) | TLR8TLR7CYP1A2ADORA2AADORA1 | |
| SCHEMBL18109482 | 0.84 | TLR8 (0.62) | TLR8TLR7CYP1A2ADORA2AADORA1 | |
| SCHEMBL18109308 | 0.82 | TLR8 (0.64) | TLR8TLR7 | |
| SCHEMBL18109312 | 0.82 | TLR8 (0.64) | TLR8TLR7 | |
| SCHEMBL18109514 | 0.81 | TLR8 (0.65) | TLR8TLR7 | |
| SCHEMBL18109517 | 0.81 | TLR8 (0.65) | TLR8TLR7 | |
| SCHEMBL18664303 | 0.76 | TLR8 (0.67) | TLR8TLR7 | |
| SCHEMBL18109268 | 0.75 | TLR8 (0.65) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR8, TLR3, TLR6 | TLR8 1/4885TLR7 4/4885CYP1A2 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.